Twist Bioscience Corporation (TWST) Tops Q2 EPS by 8c, Offers Guidance

Twist Bioscience Corporation (NASDAQ: TWST) reported Q2 EPS of ($1.04), $0.08 better than the analyst estimate of ($1.12). Revenue for the quarter came in at $60.2 million versus the consensus estimate of $56.64 million.

GUIDANCE:

Twist Bioscience Corporation sees Q3 2023 revenue of $60-61 million, versus the consensus of $72 million.

For the third quarter of fiscal year 2023, Twist provided the following financial guidance:

• Revenue is expected to be approximately $60 million to $61 million
• Gross margin is expected to be approximately 30%

For the fourth quarter of fiscal 2023, Twist provided the following financial guidance:

• Revenue is expected to be approximately $62 million to $63 million
• Gross margin is expected to be approximately 36%

For earnings history and earnings-related data on Twist Bioscience Corporation (TWST) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Twist Bioscience (TWST) PT Raised to $95 at Barclays
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance